Related Experiment Video
Updated: Aug 26, 2025
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
Top advances in lymphoma for 2021
1Washington University in St Louis School of Medicine, St Louis, MO, USA.
Abstract:
Chimeric antigen receptor (CAR) T-cell therapy, antibody-drug conjugates, bispecific T-cell redirectors, and agents targeting tonic B-cell receptor signaling have altered the paradigm for three of the most common lymphomas in the year 2021. For diffuse large B-cell lymphoma, the POLARIX study has shown improvement on the standard backbone of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in the frontline setting, a feat that had not been achieved despite great efforts over the past 20 years. In the relapsed and refractory setting, two unique CAR T-cell products have displaced autologous transplantation to the third line, and they allow patients with chemotherapy-resistant disease to receive approved therapy earlier. CAR T-cell products, once used exclusively in the aggressive lymphoma arena, are now showing high response rates and durable activity against indolent lymphomas. The investigation of mosunetuzumab in indolent lymphomas offers another option for patients who have received multiple lines of cytotoxic drugs. On the basis of these trends, PI3K inhibitors are being displaced in favor of safer and more durable constructs. In addition, within the past year, the approval and implementation of zanubrutinib for marginal zone lymphoma have filled a need for later line therapy, especially for less fit and elderly patients.
Insights
New CAR T-cell therapies and targeted agents are revolutionizing lymphoma treatment. These advancements offer improved outcomes for diffuse large B-cell lymphoma and new options for relapsed, refractory, and indolent lymphomas.
Area of Science:
- Hematology
- Oncology
- Immunotherapy
Background:
- Recent therapeutic advancements have significantly changed lymphoma treatment paradigms.
- Chimeric antigen receptor (CAR) T-cell therapy, antibody-drug conjugates, and bispecific T-cell redirectors are key innovations.
- Targeting tonic B-cell receptor signaling also represents a novel therapeutic strategy.
Purpose of the Study:
- To review the paradigm shifts in lymphoma treatment driven by novel therapeutic agents in 2021.
- To highlight the impact of these therapies on diffuse large B-cell lymphoma (DLBCL), indolent lymphomas, and marginal zone lymphoma.
- To discuss the evolving role of CAR T-cell therapy and other targeted agents in various lymphoma settings.
Main Methods:
- Review of recent clinical studies and therapeutic approvals in lymphoma treatment.
- Analysis of data from pivotal trials such as the POLARIX study for DLBCL.
- Evaluation of the efficacy and safety of novel agents including CAR T-cells, bispecific antibodies, and targeted small molecules.
Main Results:
- The POLARIX study demonstrated improved outcomes for frontline DLBCL treatment with a standard backbone plus rituximab.
- CAR T-cell therapies have become a preferred option over autologous transplantation for relapsed/refractory lymphomas, enabling earlier treatment.
- CAR T-cell therapies show promising activity in indolent lymphomas, and agents like mosunetuzumab offer new hope for heavily pretreated patients.
- Zanubrutinib approval provides a crucial later-line therapy option for marginal zone lymphoma, particularly for elderly or less fit patients.
Conclusions:
- Novel immunotherapies and targeted agents have substantially improved lymphoma treatment efficacy and patient outcomes.
- CAR T-cell therapy is expanding its role from aggressive to indolent lymphomas, offering durable responses.
- The therapeutic landscape continues to evolve, with a shift towards safer and more durable treatment constructs, displacing older agents like PI3K inhibitors.
Related Concept Videos
01:16Primary Lymphoid Organs
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy
02:56Treatment Resistant Cancers
01:18Lymphoid Cells and Tissues
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...